A real challenge, almost impossible, unworkable. Just a few of the comments made by life science lawyers keeping a close eye on the European Commission’s proposals for new rules on regulatory data protection (RDP) periods.
The general consensus seems to be that as part of its planned revision of the EU medicines legislative framework, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?